Have questions about EYLEA or Macular Edema following Retinal Vein Occlusion (MEfRVO)? We have answers.
MEfRVO occurs when a blood vessel in the retina (the light-sensitive tissue of the eye) becomes blocked by a blood clot (also called a retinal vein occlusion) and leaks fluid. Vision loss or blurring happens as the macula swells with the fluid (also called macular edema).
There are 2 main types: Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO). Each type affects different parts of the retina.
Macular Edema following CRVO (MEfCRVO) happens when the central retinal vein (the main vein that drains blood away from the retina) becomes blocked by a blood clot. Macular Edema following BRVO (MEfBRVO) happens when one or more veins branching out from the central retinal vein become blocked by a blood clot.
MEfBRVO makes up 8 out of every 10 diagnosed cases of MEfRVO and is the most common type of MEfRVO. MEfCRVO occurs less often than MEfBRVO, making up 2 out of every 10 diagnosed cases of MEfRVO.
MEfRVO may cause blurriness in the center of vision, blind spots or patches, distorted vision (wavy lines), and vision loss. These symptoms may affect your ability to read, write, drive, and recognize faces.
EYLEA is a prescription medicine approved by the Food and Drug Administration for the treatment of MEfRVO, as well as Wet Age-related Macular Degeneration (Wet AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in Patients with DME. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Your eye doctor will diagnose you with a retina condition that may be treated with EYLEA. A retina specialist is an ophthalmologist specially trained to diagnose and treat retina conditions such as MEfRVO.
EYLEA works by blocking vascular endothelial growth factor (VEGF), a protein made by the blood vessels. At high levels, VEGF can cause abnormal blood vessels to grow in the eye and leak fluid into the macula (the part of the retina responsible for sharp central vision). Blocking VEGF helps reduce the fluid leaking into the macula.
There is no cure for MEfRVO. Treatment with EYLEA, however, has been shown to help maintain or improve vision in many people with MEfRVO. In 2 clinical studies, 358 people with MEfCRVO received injections of EYLEA (2 mg) either once every 4 weeks or control. In a clinical study, 181 people with MEfBRVO received injections of EYLEA (2 mg) either once every 4 weeks or control.
The most common side effects reported in people receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
Anyone who has an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept, should not use EYLEA.
Your eye doctor will examine, wash, and numb your eye and then administer EYLEA as an injection into the eye. Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA. Talk to your eye doctor if you experience any side effects, including eye pain, redness of the eye, light sensitivity, or blurring of vision.
It is important not to miss a scheduled injection of EYLEA. If you do, be sure to make a new appointment as soon as possible.
Each person responds to treatment with EYLEA differently, including any effects of treatment. Talk with your eye doctor about your individual response and expectations over time—he or she will monitor your progress at every step of your treatment plan.
EYLEA4U® is a support program that may be able to help. Either you or your eye doctor's office can call 1-855-EYLEA4U (1-855-395-3248) Monday through Friday 9 AM to 8 PM Eastern Time to get you started.
When your eye doctor prescribes EYLEA, whether you have private or government insurance (Medicare/Medicaid) or have no insurance coverage, you can be confident that EYLEA4U is here to help. And we can conduct a Benefits Investigation with your insurer to determine your coverage for EYLEA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with:
The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.